G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer

Sponsor
Federation Francophone de Cancerologie Digestive
Study ID
NCT00541125
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 74 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: G-CSF may prevent or control neutropenia caused by first-line therapy in patients with metastatic colorectal cancer. PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia during first-line treatment with chemotherapy and bevacizumab in patients with metastatic colorectal cancer.

Key Dates

Start date
Nov 30, 2007
Status verified
May 2016
Primary completion
Sep 30, 2013
Completion
Dec 31, 2013

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Other: FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
    FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire

Primary Outcome Measure

Rate of neutropenia grade 4 or fever [ Time Frame: 2013 ]

Related Studies